Cipla inks exclusive deal with SBP Group for HER2 ADC Rolditamig Deuderuxtecan (TQB2102)
Cipla Limited signed an exclusive licensing deal with SBP Group for Rolditamig Deuderuxtecan (TQB2102), a HER2 bispecific ADC. Cipla gains rights for India, South Africa, and 5 emerging markets, handling local development and commercialization. This collaboration aims to accelerate patient access to the promising oncology therapy.
The agreement grants Cipla rights to a potentially best-in-class ADC in significant emerging markets, which is expected to enhance its oncology business and market presence, indicating a medium-term impact.
The announcement details a strategic partnership that expands Cipla's oncology portfolio and aims to improve patient access to a promising new therapy, which is a positive development for the company.
Cipla Limited has announced an exclusive licensing and supply agreement with Sino Biopharmaceutical Limited (SBP Group) for Rolditamig Deuderuxtecan, also known as TQB2102. This potential best-in-class HER2 bispecific antibody-drug conjugate (ADC) will be developed and commercialized by Cipla in India, South Africa, and five other emerging markets.
Under the terms of the agreement, Cipla will oversee local clinical development, regulatory activities, and commercialization in the licensed territories, while CTTQ, a subsidiary of SBP Group, will continue to manufacture and supply TQB2102. The collaboration aims to accelerate the development and future access to Rolditamig Deuderuxtecan for patients with breast cancer, particularly those with HER2-expressing and HER2-low advanced breast cancer.
Achin Gupta, Managing Director and Global Chief Executive Officer of Cipla, stated that the agreement strengthens Cipla's oncology portfolio and aims to expand access to this innovative treatment. Eric Tse, CEO of SBP Group, highlighted Cipla's scale and commitment to patient access as key factors in this partnership. Rolditamig Deuderuxtecan has received Breakthrough Therapy Designations from China's National Medical Products Administration.
A plain-language summary of a public exchange filing by Cipla Limited. Read the original for the full detail.